SEC Comment Letter 0000000000-23-011603 to Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc
Date: Oct. 24, 2023 · CIK: 0001541157 · Accession: 0000000000-23-011603
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275119
Letter
United States securities and exchange commission logo October 23, 2023 Rachelle Jacques Chief Executive Officer Akari Therapeutics Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Re:Akari Therapeutics Plc Registration Statement on Form F-3 Filed October 20, 2023 File No. 333-275119 Dear Rachelle Jacques: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Win Rutherfurd
Show Raw Text
United States securities and exchange commission logo
October 23, 2023
Rachelle Jacques
Chief Executive Officer
Akari Therapeutics Plc
22 Boston Wharf Road FL 7
Boston, MA 02210
Re:Akari Therapeutics Plc
Registration Statement on Form F-3
Filed October 20, 2023
File No. 333-275119
Dear Rachelle Jacques:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Win Rutherfurd